Phase I trials often use a dose-escalation design. This means that small groups of patients receive increasing doses of the new treatment until the maximum tolerated dose (MTD) is identified. The goal is to find the highest dose that can be given without causing severe side effects. Researchers closely monitor patients for any adverse reactions and collect data on how the drug is metabolized and excreted.
